Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review discusses ongoing and past trials for novel acne treatments, focusing on topical agents with potential sebosuppressive, antimicrobial, or anti-inflammatory effects, without reporting new clinical results.

New acne treatments show promise as alternatives to traditional therapies.

This article reviews key developments in pediatric dermatology for 2017, including consensus recommendations, novel genetic findings, and treatment insights for conditions like psoriasis and vascular malformations, without providing new clinical trial results.

This study demonstrates that Puerariae Lobatae Radix may regulate skin lipid metabolism by inhibiting sebaceous gland growth and reducing triglyceride secretion, highlighting its therapeutic potential for sebaceous gland-related conditions.

This review traces the historical understanding and treatment of acne across ancient Egyptian, Greek, and Roman civilizations, but provides no new clinical findings.

This review discusses psychological impacts associated with facial acne, noting that high levels of anxiety and depression among these patients are not linked to oxidative stress, and reports no new clinical results.

In this review, the authors emphasize the importance of understanding drug chemical structures to help general physicians better manage and treat acne, although no specific results are reported.

This study found that switching patients with glaucoma or ocular hypertension from benzalkonium chloride-latanoprost to preservative-free latanoprost maintained intraocular pressure control and improved tolerability, potentially enhancing treatment adherence and quality of life.

ASLAN004 was safe and well-tolerated, supporting further development for treating certain diseases.

In this case report, a combination treatment of intralesional triamcinolone acetonide, oral acitretin, and topical clobetasol propionate showed effectiveness in reducing symptoms of Graham-Little-Piccardi-Lasseur syndrome in one patient over two months, with no new areas of hair loss observed.

This article highlights the potential for latanoprost acid, a metabolite of the glaucoma medication latanoprost, to serve as an effective alternative to current treatments for androgenetic alopecia, such as minoxidil and finasteride, facilitating a faster development process for related drugs.

This review assessed the clinical and cost-effectiveness of baricitinib, an oral treatment for severe alopecia areata in adults, to inform Canadian reimbursement recommendations, excluding Quebec.

This study identified new and recurrent missense mutations in the PHGDH and PSAT1 genes, implicating them in the pathogenesis of Neu-Laxova syndrome in Chinese patients.

This CADTH recommendation advises that Olumiant should be publicly reimbursed for treating severe alopecia areata in adults, provided conditions such as a 50% scalp hair loss and specific prescribing criteria are met.

This study found that using topical latanoprost 0.005% solution significantly increased hair density and regrowth in patients with scalp alopecia areata over 12 weeks, although it did not significantly reduce hair loss area compared to the placebo.

This meta-analysis found that deuruxolitinib significantly improved hair regrowth and patient satisfaction in those with moderate to severe alopecia areata compared to placebo, though it was associated with manageable side effects such as elevated creatinine kinase levels, headaches, and acne, especially at higher doses.

In this analysis of two trials, baricitinib showed eyebrow and eyelash regrowth in severe alopecia areata patients with greater than 20% scalp hair loss at Week 36, compared to placebo.

A woman got a scalp condition from using latanoprost, but it improved after stopping the drug and starting other treatments.

In this case report, a female patient with both psoriasis and lichen planus initially responded to acitretin and topical mometasone but experienced a relapse after stopping the treatment. The authors reported marked improvement within 3 months after switching to upadacitinib, aiming to guide clinical decision-making.

This study reviewed 18 studies on the effects of ustekinumab and vedolizumab on alopecia in ulcerative colitis patients, finding varied outcomes ranging from significant hair regrowth to increased hair loss, with 65.5% experiencing regrowth and potential therapy benefits needing further exploration in larger trials.

This study identified common and previously unlisted adverse events associated with four anti-CGRP monoclonal antibodies for migraine prevention, highlighting a varied safety profile post-marketing.

In this case report, etanercept was observed to effectively resolve symptoms of refractory acrodermatitis continua suppurativa Hallopeau after previous treatments had limited success.

In this study, adult hereditary angioedema patients treated with lanadelumab at a Spanish hospital had a 94.1% reduction in angioedema episodes and needed 61% less on-demand medication, showing improved quality of life and minimal adverse effects.

In this report, a female patient with ulcerative colitis, alopecia areata, and pyoderma gangrenosum showed improvement in all three conditions after being treated with tofacitinib.

In this case study, treatment with the selective JAK1 inhibitor upadacitinib significantly improved symptoms in a patient with refractory alopecia areata, vitiligo, ankylosing spondylitis, and allergic asthma-nasal syndrome, though a transient liver function abnormality was noted.

In this study, patients with mild to moderate scalp seborrheic dermatitis experienced greater improvements in severity scores and quality of life with Lulican™ shampoo compared to Ketoconazole over four weeks, with similar safety profiles but better tolerability and cosmetic acceptability for LulicanTM.

Ivarmacitinib effectively regrows hair in severe alopecia areata.

This systematic review and meta-analysis reported that deuruxolitinib is effective for hair regrowth and improving patient-reported outcomes in individuals with moderate to severe alopecia areata, but observed manageable treatment-emergent adverse events such as elevated creatinine kinase levels and headaches, particularly with higher doses.

In this case study, upadacitinib treatment for a patient with coexisting ulcerative colitis and alopecia universalis resulted in significant hair regrowth and maintained UC remission, suggesting potential for treating similar dual-diagnosed cases.